RESUMEN

Erectile Dysfunction (ED) is one of the main complaints of aging male. A reduced production of Nitric Oxide (NO) may be involved in ED pathogenesis. NO is synthesized from l-Arginine, and asymmetrical dimethylarginine inhibits all NO synthases. DDAH1 and DDAH2 are genes that encode enzymes responsible for metabolizing ADMA. We aimed to assess whether: 1) ADMA and nitrite levels associated with ED risk and with symptoms intensity; and whether 2) DDAH1 and DDAH2 gene polymorphisms associate with changes in biochemical data, and with ED risk and symptoms intensity. In this study were included 98 healthy controls and 130 ED patients. ADMA levels were measured by ELISA and nitrite levels by Chemiluminescence. DDAH1 and DDAH2 polymorphisms were assessed by Taqman assays. We found that ED had increased nitrite levels and lower ADMA levels than Control group (P < 0.05). We found a significant correlation of ADMA with Nitrite levels only in ED (B = -0.57, P < 0.001). Genotypes and haplotypes of DDAH1 were associated with ADMA levels in ED (P < 0.05), while haplotypes of DDAH2 were associated with levels of nitrite in ED (P < 0.05). Erectile dysfunction patients show an association between DDAH1 and DDAH2 polymorphisms with ADMA levels, which in turn are negatively correlated with nitrite levels. This is not evident on healthy controls.

Asunto(s)

Amidohidrolasas/genética , Arginina/análogos & derivados , Disfunción Eréctil/sangre , Disfunción Eréctil/enzimología , Polimorfismo Genético/genética , Adulto , Anciano , Anciano de 80 o más Años , Amidohidrolasas/antagonistas & inhibidores , Amidohidrolasas/metabolismo , Arginina/sangre , Arginina/farmacología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Óxido Nítrico/biosíntesis

RESUMEN

ABSTRACT Objective: Melatonin is a hormone secreted from the pineal gland and has anti-oxidative and anti-inflammatory effects. Oxidative stress is considered as an important factor in the etiology of erectile dysfunction (ED), and in many experimental models, positive results have been obtained with melatonin treatment. This study aimed to measure serum melatonin levels in ED patients and to investigate the possible relationship between ED and melatonin levels. Materials and Methods: Sixty-two patients diagnosed with mild, moderate or severe ED according to the five-item International Erectile Function Index (IIEF-5) and 22 healthy individuals were included in the study. The serum melatonin levels, anthropometric data, and other biochemical and hormonal parameters of all the subjects were recorded. Detailed anamnesis was also obtained in terms of diabetes, hypertension, cardiovascular diseases, smoking status, and alcohol use. Results: The serum melatonin level was found 34.2±13.3 ng/dL in the mild ED group, 33.3±14.7 ng/dL in the moderate ED group, 34.8±17.2 ng/dL in the severe ED group, and 44.6±16.5 ng/dL in the control group. The serum melatonin levels were significantly lower in all ED groups compared to the control group (p=0.019). There was no significant difference in the serum melatonin levels between the three ED groups. Diabetes, hypertension, cardiovascular diseases, smoking and alcohol use were not significantly different between the ED groups (p>0.05). Conclusion: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED.

Asunto(s)

Humanos , Masculino , Disfunción Eréctil/etiología , Disfunción Eréctil/sangre , Melatonina/deficiencia , Melatonina/sangre , Triglicéridos/sangre , Índice de Severidad de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Biomarcadores/sangre , Enfermedades Cardiovasculares/complicaciones , Fumar/efectos adversos , Estudios de Casos y Controles , Colesterol/sangre , Factores de Riesgo , Estadísticas no Paramétricas , Estrés Oxidativo , Complicaciones de la Diabetes , Hipertensión/complicaciones , Persona de Mediana Edad

RESUMEN

OBJECTIVE: Melatonin is a hormone secreted from the pineal gland and has anti-oxidative and anti-inflammatory effects. Oxidative stress is considered as an important factor in the etiology of erectile dysfunction (ED), and in many experimental models, positive results have been obtained with melatonin treatment. This study aimed to measure serum melatonin levels in ED patients and to investigate the possible relationship between ED and melatonin levels. MATERIALS AND METHODS: Sixty-two patients diagnosed with mild, moderate or severe ED according to the five-item International Erectile Function Index (IIEF-5) and 22 healthy individuals were included in the study. The serum melatonin levels, anthropometric data, and other biochemical and hormonal parameters of all the subjects were recorded. Detailed anamnesis was also obtained in terms of diabetes, hypertension, cardiovascular diseases, smoking status, and alcohol use. RESULTS: The serum melatonin level was found 34.2±13.3 ng/dL in the mild ED group, 33.3±14.7 ng/dL in the moderate ED group, 34.8±17.2 ng/dL in the severe ED group, and 44.6±16.5 ng/dL in the control group. The serum melatonin levels were significantly lower in all ED groups compared to the control group (p=0.019). There was no significant difference in the serum melatonin levels between the three ED groups. Diabetes, hypertension, cardiovascular diseases, smoking and alcohol use were not significantly different between the ED groups (p>0.05). CONCLUSION: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED.

Asunto(s)

Disfunción Eréctil/sangre , Disfunción Eréctil/etiología , Melatonina/sangre , Melatonina/deficiencia , Adulto , Biomarcadores/sangre , Enfermedades Cardiovasculares/complicaciones , Estudios de Casos y Controles , Colesterol/sangre , Complicaciones de la Diabetes , Ensayo de Inmunoadsorción Enzimática , Humanos , Hipertensión/complicaciones , Masculino , Persona de Mediana Edad , Estrés Oxidativo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Fumar/efectos adversos , Estadísticas no Paramétricas , Triglicéridos/sangre

RESUMEN

Arginase 1 (ARG1) and arginase 2 (ARG2) compete with nitric oxide synthases for the substrate l-arginine. Here we aim to assess whether arginase 1 and 2 plasma levels, plasma arginase activity or genetic factors are associated with altered responsiveness to sildenafil. We studied 71 post-prostatectomy erectile dysfunction (ED) patients (PED group) and 72 clinical ED patients (CED). Patients responded to the International Index of Erectile Function questionnaire before and after the treatment. We found positive and negative correlations between plasma levels of arginase 1 and sildenafil responsiveness in the PED and CED groups, respectively. PED group also presented negative correlation between plasma arginase activity and sildenafil responsiveness. Sildenafil poor responders have shown higher plasma arginase activity in PED and higher arginase 1 levels on CED groups. In addition, variant genotypes for the rs2781659, rs2781667 and rs17599586 polymorphisms were associated with reduced arginase activity, as well as the GTTT ARG1 haplotype in CED group.

Asunto(s)

Arginasa/sangre , Arginasa/genética , Disfunción Eréctil/sangre , Disfunción Eréctil/genética , Citrato de Sildenafil/sangre , Vasodilatadores/sangre , Adulto , Anciano , Arginasa/antagonistas & inhibidores , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo Genético/genética , Citrato de Sildenafil/farmacología , Citrato de Sildenafil/uso terapéutico , Resultado del Tratamiento , Vasodilatadores/farmacología , Vasodilatadores/uso terapéutico

RESUMEN

Purpose: To evaluate the expression of endothelial and inducible NOS in addition to the miRNA-27b in the corpus cavernosum and peripheral blood of healthy rats, diabetic rats, alcoholic rats and rats with both pathologies. Methods: Forty eight Wistar rats were divided into four groups: control (C), alcoholic (A), diabetic (D) and alcoholic-diabetic (AD). Samples of the corpus cavernosum were prepared to study protein expressions of eNOS and iNOS by immunohistochemistry and expression of miRNA-27b in the corpus cavernosum and peripheral blood. Results: Immunohistochemistry for eNOS and iNOS showed an increase in cavernosal smooth muscle cells in the alcoholic, diabetic and alcoholic-diabetic groups when compared with the control group. Similarly, the mRNA levels for eNOS were increased in cavernosal smooth muscle (CSM) in the alcoholic, diabetic and alcoholic-diabetic groups and miRNA-27b were decreased in CSM in the alcoholic, diabetic and alcoholic-diabetic groups. Conclusion: The major new finding of our study was an impairment of relaxation of cavernosal smooth muscle in alcoholic, diabetic, and alcoholic-diabetic rats that involved a decrease in the nitric oxide pathway by endothelium-dependent mechanisms accompanied by a change in the corpus cavernosum contractile sensitivity.(AU)

Asunto(s)

Animales , Ratas , Alcoholismo/sangre , /biosíntesis , Factores Relajantes Endotelio-Dependientes/antagonistas & inhibidores , MicroARNs/química , Diabetes Mellitus/sangre , Disfunción Eréctil/sangre , Genómica/tendencias

RESUMEN

Arginase 1 and Arginase 2 are homologous enzymes that convert l-Arginine to Urea and l-ornithine and compete with nitric oxide synthases for l-Arginine. Increased Arginase 1 and 2 activity may reduce nitric oxide production by the endothelium in disease states, including erectile dysfunction (ED). Here we aimed at assessing whether Arginase 1 and 2 plasma levels, plasma arginase activity, or genetic factors are associated with ED risk and severity. Blood samples were collected from healthy controls (n = 106) and from patients with ED (n = 110) after completion of the IIEF questionnaire (international index of erectile function). Plasma Arginase 1 and 2 concentrations were assessed by ELISA, while plasma arginase activity was measured by spectrophotometry. Genotypes of ARG1 (rs2781659, rs2781667, rs2246012 and rs17599586) and ARG2 (rs3742879 and rs10483801) were determined by Taqman genotyping assays by real-time polymerase chain reaction. Increased Arginase 2 concentrations were found in clinical ED and are associated with increased risk for ED. ARG1 rs2781659 AA and rs2781667 TT genotypes are associated with lower IIEF scores (higher severity) only in clinical ED. Similarly, the ARG1 GTCC haplotype is associated with higher IIEF scores in clinical ED. This study shows that plasma Arginase 2 concentrations may serve as risk factor for ED. Besides, Arginase 1 genetic variations affect ED severity.

Asunto(s)

Arginasa/sangre , Arginasa/genética , Disfunción Eréctil/enzimología , Disfunción Eréctil/genética , Polimorfismo Genético , Adulto , Anciano , Anciano de 80 o más Años , Disfunción Eréctil/sangre , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios

RESUMEN

Inflammatory markers like tumour necrosis factor-alpha (TNF-α) have been related to erectile dysfunction (ED) and may interact with other cardiovascular risk factors such as obstructive sleep apnoea syndrome (OSAS). The aim of this study was to examine the inflammatory, metabolic and hormonal profile of men with or without ED complaints and/or OSAS recruited through the Epidemiologic Sleep Study (EPISONO). A sample of 363 men completed sexual questionnaires for ED and had physical and blood examinations. OSAS was evaluated by polysomnography and clinical assessment. The blood samples were used for determination of TNF-α, interleukin-6, leptin, cholesterol and fractions, triglycerides, homocysteine, glucose and hormonal levels. After controlling for confounding factors, men with ED complaints presented higher systolic blood pressure and TNF-α, independent of OSAS. Significant interaction between ED and OSAS was only observed for neck circumference, which was higher in ED men with OSAS than men with OSAS without ED and men with ED without OSAS. Binary logistic regression showed that the predictor factors for ED were age >43 years, myocardial infarction events, TNF-α and systolic blood pressure. Finally, a receiver-operating characteristics curve suggested a cut-off point of 9.95 pg/mL for TNF-α with sensitivity of 60% and specificity of 59% in men with ED complaints. Furthermore, there was a significant association between high levels of TNF-α (>9.95 pg/mL) and the presence of ED complaints. The results showed that there was an association between TNF-α levels and ED complaints in men independent of OSAS.

Asunto(s)

Disfunción Eréctil/fisiopatología , Apnea Obstructiva del Sueño/sangre , Factor de Necrosis Tumoral alfa/sangre , Adulto , Presión Sanguínea , Brasil/epidemiología , Disfunción Eréctil/sangre , Disfunción Eréctil/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Cuello/anatomía & histología , Apnea Obstructiva del Sueño/epidemiología , Apnea Obstructiva del Sueño/fisiopatología

RESUMEN

INTRODUCTION: Epileptic men may experience hormonal changes that may alter semen quality and sexual function. Alterations in male sexual and reproductive parameters may also be due to treatment with antiepileptic drugs to control seizures. AIMS: To evaluate serum hormone concentrations, semen quality, the frequency of sexual intercourse (FSI), and erectile function in men with epileptic seizures controlled by carbamazepine (CBZ). MAIN OUTCOME MEASURES: The five-question form of the International Index of Erectile Function (IIEF-5), and semi-structured questionnaire. METHODS: One hundred and eighteen men, aged 18-45 years, were included in this controlled, cross-sectional study: 63 men taking CBZ (epileptic group) were compared to 55 healthy men (control group). Blood sample was collected to determine hormones concentrations. Erectile function and the frequency of sexual relations were assessed by using questionnaires. Sperm morphology was analyzed by examining the quality of the head, intermediate part and tail of the spermatozoa. RESULTS: Using the IIEF-5, we observed a significant association between erectile dysfunction (ED) and groups (P < 0.01), where epileptic men had 17.33 (95% CI 3.59, 83.52) odds to have erectile dysfunction. Adjusted odds ratio to group considering luteinizing hormone, prolactin, Serum total testosterone, androstenedione, and dehydroepiandrosterone, androstenedione levels and free androgen index, we observed only group effect where epileptic men had 10.47 (95% CI 2.75, 39.83) odds to have FSI < 3 times a week. Sperm vitality was altered in 27% of the epileptic subjects compared with 5.4% of the control group (P < 0.002). Sperm motility differed significantly between groups, with A + B motility ≤50% observed in 98.4% of the epileptic group and in 85.4% of the control group (P < 0.01). Sperm morphology <14% was observed in 93.7% of the epileptic men, compared with 34.6% of the controls (P < 0.001). CBZ users, showed less sexual intercourse then controls (P ≤ 0.001). CONCLUSIONS: Epileptic men taking CBZ present with changes in hormonal levels, altered semen quality, ED, and a reduction in coital frequency.

Asunto(s)

Anticonvulsivantes/efectos adversos , Carbamazepina/efectos adversos , Epilepsia del Lóbulo Temporal/tratamiento farmacológico , Disfunción Eréctil/inducido químicamente , Análisis de Semen , Conducta Sexual/efectos de los fármacos , Adolescente , Adulto , Anticonvulsivantes/uso terapéutico , Carbamazepina/uso terapéutico , Estudios Transversales , Epilepsia del Lóbulo Temporal/sangre , Disfunción Eréctil/sangre , Disfunción Eréctil/diagnóstico , Hormonas Esteroides Gonadales/sangre , Humanos , Masculino , Motilidad Espermática/efectos de los fármacos , Adulto Joven

RESUMEN

INTRODUÇÃO: A doença cardiovascular é a causa mais comum de morte em todo o mundo. Em homens, 50% das mortes por doença arterial coronariana ocorre em indivíduos sem história prévia de doença cardiovascular. Disfunção erétil e doença arterial coronariana têm uma relação estreita, já que ambas são consequências de disfunção endotelial, levando a limitações no fluxo sanguíneo. A associação entre severidade da disfunção erétil e a extensão das lesões da doença arterial coronariana ao exame angiográfico sugere que homens com disfunção erétil sejam considerados sob risco aumentado de doença arterial coronariana. OBJETIVO: Avaliar o papel da disfunção erétil como manifestação sentinela e/ou marcador de risco para doença arterial coronariana. MÉTODOS: Realizou-se uma análise secundária com dados previamente coletados em dois projetos (“Projeto Avaliar” e “Projeto Ampliar”). Pacientes do sexo masculino, com idade >18 anos, foram convidados a participar das duas pesquisas sobre disfunção erétil ao comparecerem a uma consulta médica ambulatorial em 2002-2003 (Projeto Avaliar) e em 2003-2004 (Projeto Ampliar)...

---

INTRODUCTION: Cardiovascular disease is the most common cause of death worldwide. In men, 50% of deaths due to coronary artery disease occur among those without previous history of cardiovascular disease. Erectile dysfunction and coronary artery disease are closely related, since they are both consequences of endothelial dysfunction, leading to restrictions on the blood flow. The association between the severity of erectile dysfunction and the angiographic extension of coronary artery disease suggests that men with erectile dysfunction be considered at increased risk for coronary artery disease. OBJECTIVES: To evaluate the role of erectile dysfunction as a sentinel sign and/or surrogate of risk for coronary artery disease. METHODS: We performed a secondary analysis on data previously collected in two research projects (“Projeto Avaliar” e “Projeto Ampliar”). Male patients, age 18 years old or more, were invited to participate in two surveys about erectile dysfunction while attending a routine office visit or consultation in 2002-2003 (Projeto Avaliar) and in 2003-2004 (Projeto Ampliar)...

Asunto(s)

Humanos , Disfunción Eréctil/diagnóstico , Disfunción Eréctil/mortalidad , Disfunción Eréctil/patología , Disfunción Eréctil/prevención & control , Disfunción Eréctil/sangre

RESUMEN

FUNDAMENTO: A Disfunção Erétil (DE) se associa ao risco aumentado de Doença Arterial Coronariana (DAC). OBJETIVO: Avaliar a associação entre DE, determinada pelo Índice Internacional de Função Erétil Simplificado (IIFE-5), e DAC. MÉTODOS: Estudo de corte transversal que avaliou 263 hipertensos (55 [50 - 61] anos). A DE foi avaliada pelo IIEF-5 e a DAC, por meio da história de revascularização miocárdica prévia e/ou por cineangiocoronariografia. RESULTADOS: O IIFE-5 se correlacionou com o clearance de creatinina [ClCr] (Rho = 0,23; p < 0,001) e com a idade (Rho = -0,22; p < 0,001). Quarenta e dois pacientes apresentavam DAC; e o IIFE-5 foi capaz de discriminá-los (área sob a curva ROC = 0,63; p = 0,006). Os pacientes foram divididos em dois grupos: IIFE-5 < 20 (n = 140) e IIFE- 5 > 20 (n = 123); aqueles com menor IIFE-5 tinham idade mais elevada (57 [52 - 61] vs. 54 [45 - 60] anos; p = 0,002), maior prevalência de DAC (22% vs. 9%; p = 0,004), tabagismo (64% vs. 47%; p = 0,009) e do uso de inibidores dos canais de cálcio (65 % vs. 43%; p = 0,001), além de menor ClCr (67,3 [30,8 - 88,6] vs. 82,6 [65,9 - 98,2] ml/min; p < 0,001). O IIFE-5 < 20 se associou ao maior risco de DAC em regressão logística; tanto univariada (RR = 2,89 [IC 95% 1,39 - 6,05]), quanto após ajustes para idade, diabetes, ClCr, tabagismo, pressão arterial média e uso de anti- hipertensivos (RR = 2,59 [IC 95%: 1,01 - 6,61]). CONCLUSÃO: O IIFE-5 se associa ao diagnóstico de DAC e sua utilização pode agregar informação ao estadiamento do risco cardiovascular em pacientes hipertensos.

---

BACKGROUND: Erectile Dysfunction (ED) is associated with increased risk of coronary artery disease (CAD). OBJECTIVE: To evaluate the association between ED, determined by the Simplified International Index of Erectile Function (IIEF-5) and CAD. METHODS: This was a cross-sectional cohort study that evaluated 263 hypertensive patients (55 [50-61] years). ED was assessed through the IIEF-5 and CAD by the history of previous myocardial revascularization and/or coronary angiography. RESULTS: The IIEF-5 correlated with creatinine clearance [CrCl] (Rho = 0.23, p <0.001) and age (Rho = -0.22, p <0.001). Forty-two patients had CAD, and IIEF-5 was able to discriminate them (area under the ROC curve = 0.63, p = 0.006). Patients were divided into two groups: IIEF-5 < 20 (n = 140) and IIEF-5 > 20 (n = 123); those with lower IIEF-5 scores were older (57 [52-61] vs. 54 [45-60] years, p = 0.002), had higher prevalence of CAD (22% vs. 9%, p = 0.004), smoking (64% vs. 47%, p = 0.009) and use of calcium channel inhibitors (65% vs. 43.%, p = 0.001), as well as lower CrCl (67.3 [30.8 to 88.6] vs. 82.6 [65.9 - 98.2] ml/min, p <0.001). The IIEF-5 < 21 was associated with increased risk of CAD in the logistic regression, both univariate (RR = 2.89 [95%CI: 1.39 - 6.05]), and after adjusting for age, diabetes, CrCl, smoking, mean arterial pressure and use of antihypertensive drugs (RR = 2.59 [95% CI: 1.01 - 6.61]). CONCLUSION: The IIEF-5 is associated with the diagnosis of CAD and its use can add information to cardiovascular risk staging in hypertensive patients.

Asunto(s)

Humanos , Masculino , Persona de Mediana Edad , Enfermedad de la Arteria Coronaria/etiología , Disfunción Eréctil/complicaciones , Hipertensión/sangre , Presión Sanguínea/fisiología , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/diagnóstico , Enfermedad de la Arteria Coronaria/fisiopatología , Métodos Epidemiológicos , Disfunción Eréctil/sangre , Disfunción Eréctil/fisiopatología , Hipertensión/fisiopatología , Factores de Riesgo , Índice de Severidad de la Enfermedad

RESUMEN

BACKGROUND: Erectile Dysfunction (ED) is associated with increased risk of coronary artery disease (CAD). OBJECTIVE: To evaluate the association between ED, determined by the Simplified International Index of Erectile Function (IIEF-5) and CAD. METHODS: This was a cross-sectional cohort study that evaluated 263 hypertensive patients (55 [50-61] years). ED was assessed through the IIEF-5 and CAD by the history of previous myocardial revascularization and/or coronary angiography. RESULTS: The IIEF-5 correlated with creatinine clearance [CrCl] (Rho = 0.23, p <0.001) and age (Rho = -0.22, p <0.001). Forty-two patients had CAD, and IIEF-5 was able to discriminate them (area under the ROC curve = 0.63, p = 0.006). Patients were divided into two groups: IIEF-5 < 20 (n = 140) and IIEF-5 > 20 (n = 123); those with lower IIEF-5 scores were older (57 [52-61] vs. 54 [45-60] years, p = 0.002), had higher prevalence of CAD (22% vs. 9%, p = 0.004), smoking (64% vs. 47%, p = 0.009) and use of calcium channel inhibitors (65% vs. 43.%, p = 0.001), as well as lower CrCl (67.3 [30.8 to 88.6] vs. 82.6 [65.9 - 98.2] ml/min, p <0.001). The IIEF-5 < 21 was associated with increased risk of CAD in the logistic regression, both univariate (RR = 2.89 [95%CI: 1.39 - 6.05]), and after adjusting for age, diabetes, CrCl, smoking, mean arterial pressure and use of antihypertensive drugs (RR = 2.59 [95% CI: 1.01 - 6.61]). CONCLUSION: The IIEF-5 is associated with the diagnosis of CAD and its use can add information to cardiovascular risk staging in hypertensive patients.

Asunto(s)

Enfermedad de la Arteria Coronaria/etiología , Disfunción Eréctil/complicaciones , Hipertensión/sangre , Presión Sanguínea/fisiología , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/diagnóstico , Enfermedad de la Arteria Coronaria/fisiopatología , Métodos Epidemiológicos , Disfunción Eréctil/sangre , Disfunción Eréctil/fisiopatología , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Factores de Riesgo , Índice de Severidad de la Enfermedad

RESUMEN

OBJECTIVE: To evaluate whether the response to on-demand vardenafil could be improved by its daily usage in hypertensive men with erectile dysfunction (ED) who previously did not answer to on-demand regime. METHODS: Our main efficacy criterion was per patient percentage of positive answers on the Sexual Encounter Profile question 3 (SEP3). Carotid intima-media thickness (IMT), flow-mediated dilation (FMD), and nitrate-mediated dilation on brachial artery were considered as vascular parameters. A total of 74 hypertensive men with ED aged 50 to 70 years with no major cardiovascular disease were selected from 284 patients initially referred. After vardenafil on-demand usage during 4 weeks, patients with more than 50% of positive answers on the SEP3, or 50% and more than 6 points on the International Index of Erectile Function-Erection Function Domain (IIEF-EF) basal score or positive answer to global evaluation question were considered "responders." "Nonresponders" (n = 35) were randomized to daily vardenafil 10 mg or placebo during 5 weeks along with open 10 mg of vardenafil before intercourse. RESULTS: In the active group, 38.8% of patients became responders to vardenafil (P < .05). Clinical response to continuous vardenafil correlated with sexual frequency (r = .68, P < .01), Framingham risk score (r = -.65, P < .01), carotid IMT (r = -.61, P = .01) and low-density lipoprotein (LDL)-cholesterol (r = -.64, P < .01). CONCLUSION: Daily vardenafil during 5 weeks rescued response to on-demand regime among ED hypertensive men with no major cardiovascular disease. Further clinical trials and cost-effectiveness studies are necessary to confirm these findings.

Asunto(s)

Disfunción Eréctil/tratamiento farmacológico , Imidazoles/administración & dosificación , Inhibidores de Fosfodiesterasa 5/administración & dosificación , Piperazinas/administración & dosificación , Anciano , Glucemia/metabolismo , Arteria Braquial/efectos de los fármacos , Arteria Braquial/fisiología , Grosor Intima-Media Carotídeo , LDL-Colesterol/sangre , Disfunción Eréctil/sangre , Disfunción Eréctil/complicaciones , Humanos , Hipertensión/complicaciones , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Nitratos/farmacología , Sulfonas/administración & dosificación , Encuestas y Cuestionarios , Resultado del Tratamiento , Triazinas/administración & dosificación , Diclorhidrato de Vardenafil

RESUMEN

INTRODUCTION: Erectile dysfunction (ED) is highly prevalent among type 2 diabetes mellitus patients (T2DM). Although a link among systemic inflammation, endothelial dysfunction, and ED is described in clinical situations mainly related with coronary heart disease (CHD) risk, evidences of this link in T2DM patients are rather limited. AIMS: To evaluate the association between endothelial dysfunction and balance of pro-/anti-inflammatory mediators with ED presence and severity in T2DM. METHODS: We conducted a cross-sectional study of 190 T2DM patients without symptomatic CHD, 150 out of them with ED and 40 without ED. Serum levels of E-selectin, intercellular adhesion molecule-1, tumor necrosis factor-α (TNF-α), and interleukin (IL)-10 were measured using specific enzyme-linked immunosorbent assays (ELISAs). ED presence and severity were tested by the five-item version of the International Index of Erectile Function questionnaire. MAIN OUTCOME MEASURES: Differences in circulating levels of endothelial dysfunction (ICAM-1, E-selectin) and inflammatory/anti-inflammatory (TNF-α, IL-10, TNF-α : IL-10 ratio) markers between T2DM patients with and without ED, and assessment of biomarkers ED predictive value while adjusting for other known ED risk factors. RESULTS: Patients with ED were older and had longer duration of diabetes than patients without ED. E-selectin serum levels were significantly increased, while IL-10 were lower in patients with ED; because TNF-α levels tend to be higher, TNF-α : IL-10 ratio was more elevated in ED patients. No significant differences of ICAM-1 levels were observed between study groups. Endothelial activation markers and TNF-α, as well as diabetes duration, were negatively correlated with erectile function. On multivariate analysis including age, duration of diabetes, insulin treatment, hypertension, insulin resistance, fair-to-poor glycemic control, and metabolic syndrome, increments in E-selectin levels and TNF-α : IL-10 ratio predicted independently ED presence, while IL-10 increases were associated with lower risk of ED in T2DM patients. CONCLUSIONS: ED in T2DM patients without symptomatic CHD is associated with systemic endothelial dysfunction and a predominant, imbalanced low-grade inflammatory response.

Asunto(s)

Diabetes Mellitus Tipo 2/inmunología , Endotelio Vascular/inmunología , Disfunción Eréctil/inmunología , Enfermedades Vasculares/inmunología , Adulto , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Selectina E/sangre , Disfunción Eréctil/sangre , Humanos , Inflamación/sangre , Inflamación/inmunología , Molécula 1 de Adhesión Intercelular/sangre , Interleucina-10/sangre , Masculino , Persona de Mediana Edad , Factor de Necrosis Tumoral alfa/sangre , Enfermedades Vasculares/sangre

RESUMEN

Erectile dysfunction (ED) can be affected by androgen levels, which exert their action through the androgen receptor (AR). Androgenic action has been demonstrated to inversely correlate with a polymorphic trinucleotide CAG repeat region in the AR gene. We conducted an epidemiologic study to determine the potential association between the CAG repeat polymorphism of the AR gene and ED complaints, gonadal steroids, and sleep parameters in a large population-based sample in São Paulo, Brazil. AR CAG repeat was genotyped in 79 men with ED complaints and in 340 controls. Sleep and hormonal profiles were measured in all men. There was no association between the AR CAG repeat polymorphism and ED complaints. Moreover, there was no significant correlation among free and total testosterone, estradiol, follicle-stimulating hormone, and luteinizing hormone levels, as well as sleep parameters with the CAG repeat length, when evaluating the population as a whole, as well as subdivided into ED and control groups independently. The results were not affected when the data were analyzed in quartiles, divided by the median of the sample, or after correction for population stratification. AR CAG repeat polymorphism is not associated with ED complaints, gonadal steroids, and sleep parameters in men from a population-based sample in Brazil.

Asunto(s)

Disfunción Eréctil/genética , Hormonas Esteroides Gonadales/sangre , Polimorfismo Genético , Receptores Androgénicos/sangre , Receptores Androgénicos/genética , Sueño , Repeticiones de Trinucleótidos/genética , Brasil , Recolección de Datos , Disfunción Eréctil/sangre , Genotipo , Hormonas Esteroides Gonadales/genética , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa

RESUMEN

La erección depende de la liberación de óxido nítrico (ON) endotelial. La insulinorresistencia (IR) produce disfunción endotelial por menor síntesis y liberación de ON. El tratamiento con metformina mejora la función eréctil en ratones con IR y disfunción eréctil (DE). Objetivos: Evaluar en pacientes con DE: 1) la presencia de IR; 2) el grado de severidad de la DE según la presencia de IR y 3) el efecto del tratamiento con metformina sobre la función eréctil en pacientes con DE e IR. Material y métodos: Estudio prospectivo, randomizado, doble ciego con placebo. Se incluyeron 81 pacientes con DE y 20 hombres sin DE (grupo control). Se evaluó función eréctil con el cuestionario IIEF-5. Se evaluó IR con el índice HOMA. Se consideró IR si HOMA ≥3. Treinta pacientes con DE, IR y pobre respuesta al sildenafil fueron randomizados para recibir tratamiento con metformina o placebo. Resultados: Se encontró una diferencia significativa entre pacientes con DE y el grupo control en HOMA: 4.9±2.8 versus 3.6±2.6 (p=0.03). La prevalencia de IR fue mayor en los pacientes con DE que en el grupo control: 77.7% versus 45.0% (p=0.008). Se halló una correlación negativa entre HOMA e IIEF-5: r:-0.21 (p=0.04). Los pacientes con DE e IR tuvieron menor score IIEF-5 que los pacientes con DE sin IR. Luego del tratamiento con metformina, los pacientes con DE tuvieron un incremento significativo en el score IIEF-5 y una disminución significativa del HOMA a los 2 y 4 meses de tratamiento, no se observaron cambios en IIEF-5 ni HOMA en los pacientes que recibieron placebo. Conclusión: nuestros hallazgos hacen suponer que la disfunción endotelial causada por IR podría ser uno de los mecanismos fisiopatológicos de la DE. El tratamiento con metformina en pacientes con DE reduce la IR y podría mejorar la respuesta al tratamiento con sildenafil. Rev Argent Endocrinol Metab 47: 13-20, 2010. Los autores declaran no tener conflictos de interés.

---

Erection depends largely on the release of nitric oxide (NO) by vascular endothelium. Insulin resistance (IR), present in most subjects who have obesity, metabolic syndrome (MS) or type 2 diabetes mellitus (DM2) is a metabolic abnormality that produces endothelial dysfunction determined by minor synthesis and release of NO. Treatment with metformin improves erectile function in mice with erectile dysfunction (ED) and IR. Aims: To evaluate in ED patients: 1) the presence of IR; 2) the degree of severity of ED according to the presence of IR; 3) the effect of treatment with metformin on erectile function in patients with ED and IR. Methods: Prospective, randomized, controlled, double-blind placebo study. We included 81 patients with ED and 20 men without ED (control group). Exclusion criteria: pharmacologic, anatomic or endocrine ED (hypogonadism or hyperprolactinemia), DM2, prior prostatic surgery or chronic illnesses. The erectile function was rated according the International Index of Erectile Function 5. IR was measerud by HOMA index. Thirty patients with ED, IR and poor response to sildenafil were randomized to receive metformin or placebo. Results: Patients with ED had higher HOMA index versus control group: 4.9 ± 2.8 versus 3.6 ± 2.6, p=0.03. The prevalence of IR was higher in ED group versus control group: 77.7% versus 45.0%, p=0.008. We found a negative correlation between HOMA and IIEF-5: r:-0.21, p=0.04. Patients with ED and IR (n=62) had lower IIEF-5 score when compared with those without IR (n=19): 13.6 ± 4.3 versus 16.0 ± 3.1, p=0.04. After treatment with metformin patients with ED showed a significant increase in IIEF-5 score and a significant decrease in HOMA index both at 2 and 4 months of treatment. Changes in the IIEF-5 score and HOMA index were not observed in patients with ED receiving placebo. Conclusion: Our findings suggest that endothelial dysfunction caused by IR could be one of the pathophysiologial mechanisms of ED. Treatment with metformin in patients with ED reduces IR and could improve response to treatment with sildenafil. Rev Argent Endocrinol Metab 47: 13-20, 2010 No competing finantial interests exist.

Asunto(s)

Humanos , Masculino , Adulto , Persona de Mediana Edad , Anciano , Disfunción Eréctil/etiología , Disfunción Eréctil/tratamiento farmacológico , Metformina/uso terapéutico , Placebos , Resistencia a la Insulina/fisiología , Método Doble Ciego , Disfunción Eréctil/sangre

RESUMEN

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p < 0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.

Asunto(s)

Carbolinas/farmacología , Dipeptidasas/metabolismo , Disfunción Eréctil/sangre , Disfunción Eréctil/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Inhibidores de Fosfodiesterasa 5/farmacología , Adulto , Estudios de Casos y Controles , Humanos , Masculino , Persona de Mediana Edad , Tadalafilo

RESUMEN

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.

Asunto(s)

Adulto , Humanos , Masculino , Persona de Mediana Edad , Carbolinas/farmacología , Dipeptidasas/metabolismo , Disfunción Eréctil/sangre , Disfunción Eréctil/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , /farmacología , Estudios de Casos y Controles

RESUMEN

BACKGROUND: Neurohormonal activation and abnormalities in growth hormone and testosterone concentrations have been reported in heart failure (HF). Erectile dysfunction(ED) is common in these patients and contributes to a low quality of life. No data are known regarding the correlation between testosterone and hemodynamics, exercise capacity and cardiac function in HF patients with ED, a marker of endothelial dysfunction. The aim of this study was to correlate testosterone levels with cardiac function, hemodynamic and exercise capacity in HF patients with ED. MATERIALS AND METHODS: Fifteen HF patients underwent a six-minute treadmill cardiopulmonary walking test (6'CWT) and, ten minutes later, a maximum cardiopulmonary exercise test. Also, testosterone and other hormones were determined at rest. RESULTS: Among hemodynamic variables only diastolic blood pressure on 6'CWT was correlated with testosterone levels(r=-0.66, p=0.007). The variables on exercise tests, VE/VCO2 slope and oxygen consumption did not show any correlation, except the distance at 6'CWT (r=0.50, p=0,047). Right and left ventricle ejection fraction showed inverse correlation with testosterone (r=-0.55, p=0.03 and r=-0.69, p=0.004 respectively). CONCLUSION: Testosterone levels correlated directly with distance at six-minute cardiopulmonary walk test and inversely with diastolic blood pressure, right and left ventricle ejection fraction in heart failure patients with erectile dysfunction. Further elucidation of mechanisms as regards testosterone action in these patients is warranted.

Asunto(s)

Presión Sanguínea/fisiología , Disfunción Eréctil/fisiopatología , Insuficiencia Cardíaca/fisiopatología , Testosterona/sangre , Disfunción Ventricular Izquierda/fisiopatología , Disfunción Eréctil/sangre , Disfunción Eréctil/etiología , Prueba de Esfuerzo , Tolerancia al Ejercicio/fisiología , Estado de Salud , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Estadísticas no Paramétricas , Volumen Sistólico/fisiología , Factores de Tiempo

RESUMEN

BACKGROUND: Neurohormonal activation and abnormalities in growth hormone and testosterone concentrations have been reported in heart failure (HF). Erectile dysfunction(ED) is common in these patients and contributes to a low quality of life. No data are known regarding the correlation between testosterone and hemodynamics, exercise capacity and cardiac function in HF patients with ED, a marker of endothelial dysfunction. The aim of this study was to correlate testosterone levels with cardiac function, hemodynamic and exercise capacity in HF patients with ED. MATERIALS AND METHODS: Fifteen HF patients underwent a six-minute treadmill cardiopulmonary walking test (6'CWT) and, ten minutes later, a maximum cardiopulmonary exercise test. Also, testosterone and other hormones were determined at rest. RESULTS: Among hemodynamic variables only diastolic blood pressure on 6'CWT was correlated with testosterone levels(r =- 0.66, p = 0.007). The variables on exercise tests, VE/VCO2 slope and oxygen consumption did not show any correlation, except the distance at 6'CWT (r = 0.50, p = 0,047). Right and left ventricle ejection fraction showed inverse correlation with testosterone (r =- 0.55, p = 0.03 and r =- 0.69, p = 0.004 respectively). CONCLUSION: Testosterone levels correlated directly with distance at six-minute cardiopulmonary walk test and inversely with diastolic blood pressure, right and left ventricle ejection fraction in heart failure patients with erectile dysfunction. Further elucidation of mechanisms as regards testosterone action in these patients is warranted.

Asunto(s)

Humanos , Masculino , Persona de Mediana Edad , Presión Sanguínea/fisiología , Disfunción Eréctil/fisiopatología , Insuficiencia Cardíaca/fisiopatología , Testosterona/sangre , Disfunción Ventricular Izquierda/fisiopatología , Prueba de Esfuerzo , Disfunción Eréctil/sangre , Disfunción Eréctil/etiología , Tolerancia al Ejercicio/fisiología , Estado de Salud , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/complicaciones , Estadísticas no Paramétricas , Volumen Sistólico/fisiología , Factores de Tiempo

RESUMEN

OBJECTIVE: To evaluate the association between the levels of glycosylated haemoglobin (HbA1c) and the severity of erectile dysfunction (ED) in men with diabetes mellitus (DM). PATIENTS AND METHODS: This cross-sectional study included sexually active men with a diagnosis of DM attending a urological medical centre from January 2000 to December 2001. The 115 men with ED (95%) completed the International Index of Erectile Function questionnaire, and fasting serum glucose and HbA1c serum levels were measured. The relationship between the severity of ED and serum HbA1c levels was assessed. RESULTS: Of men with HbA1c levels of < 8%, half had mild, and 18% and 32% had moderate and severe ED, respectively (P = 0.038); of men with HbA1c levels of > or = 8%, 25%, 29%, and 46% had mild, moderate and severe ED, respectively (P = 0.008). In addition, men with HbA1c levels of > or = 11% had a statistically higher prevalence of severe ED (P = 0.002). There was no difference in severity of ED in the HbA1c subgroups when the duration of DM was < or = 5 years (P = 0.87), but most men with HbA1c levels of > or = 8% and a history of DM of 6-10 or > 10 years had severe ED (P < 0.03). CONCLUSION: This study suggests that the severity of ED is associated with increasing HbA1c levels in diabetic men.

Asunto(s)

Diabetes Mellitus/sangre , Disfunción Eréctil/sangre , Hemoglobina Glucada/análisis , Adulto , Anciano , Anciano de 80 o más Años , Glucemia/análisis , Estudios Transversales , Disfunción Eréctil/etiología , Humanos , Masculino , Persona de Mediana Edad